Micro lesion effect of the globus pallidus internus with deep brain stimulation in Parkinson's disease patients

Yi Wang1, Peng Li1, FeiLong Gong1

  • 1Department of Neurosurgery, West China Hospital, Sichuan University, Guoxue Alley 37, Chengdu, China.

Acta Neurochirurgica
|July 30, 2017
PubMed
Abstract

Insights

The micro-lesion effect (MLE) after globus pallidus internus deep brain stimulation (GPi DBS) predicts long-term Parkinson's disease improvement. This effect, particularly its magnitude and duration, correlates with better outcomes when patients are off medication.

Area of Science:

  • Neurosurgery
  • Neurology
  • Biomedical Engineering

Background:

  • The micro-lesion effect (MLE) is known in Parkinson's disease (PD) patients undergoing deep brain stimulation (DBS), particularly for subthalamic nucleus (STN) targets.
  • Research on the MLE in globus pallidus internus (GPi) DBS is limited.
  • This study investigates the correlation between MLE and GPi DBS efficacy in PD.

Purpose of the Study:

  • To determine if the micro-lesion effect (MLE) in globus pallidus internus (GPi) deep brain stimulation (DBS) predicts long-term outcomes in Parkinson's disease (PD) patients.
  • To explore the relationship between the magnitude and duration of the MLE and clinical improvements.
  • To assess the influence of medication on the MLE and its predictive value.

Main Methods:

  • 36 PD patients receiving GPi DBS were evaluated preoperatively and at multiple time points up to 1 year post-surgery.
  • Assessments included UPDRS III scores (on/off medication), daily off-medication time, and severe dyskinesia time.
  • L-dopa dosage, MLE magnitude, and MLE duration were recorded.

Main Results:

  • 32 patients exhibited a postoperative MLE.
  • A significant correlation was found between MLE magnitude and UPDRS III improvement at 6 and 12 months (off-medication).
  • MLE duration also predicted long-term, off-medication improvement, though no correlation was observed with on-medication status. Postoperative improvements in UPDRS III, off-time, and dyskinesia were noted.

Conclusions:

  • The MLE following GPi DBS is a valuable predictor of long-term treatment benefit in Parkinson's disease.
  • Medication status may influence the MLE's predictive power, suggesting complex interactions.
  • Further research is needed to elucidate the precise mechanisms underlying the MLE in GPi DBS.